‘Alternating' bouts of constipation and diarrhoea could signal three major diseases
Changes in bowel movements can reveal a lot about a person's health. (Source: Daily Express - Health)
Source: Daily Express - Health - November 13, 2022 Category: Consumer Health News Source Type: news
How Dr TikTok could cause major health problems
Medical experts have warned young people against copying health advice from influencers on TikTok which could leave them with liver disease, cancer or even 'wind and diarrhoea'. (Source: the Mail online | Health)
Source: the Mail online | Health - November 5, 2022 Category: Consumer Health News Source Type: news
WHO Regional Director ’s statement on cholera outbreaks
2 November 2022 – Good afternoon and welcome to today’s press briefing on the latest updates on cholera outbreaks in the Eastern Mediterranean Region.
After decades without a single case of cholera, the outbreaks that have been recently declared in Lebanon and Syria mark an unwelcome comeback in those countries. In fact, this is part of a worsening pattern across the Region, and the globe, as 8 of the 22 countries in our Region are grappling with outbreaks of cholera and acute watery diarrhoea.
Moreover, there are now 29 cholera outbreaks worldwide – the highest number on record. We know that...
Source: WHO EMRO News - November 2, 2022 Category: Middle East Health Source Type: news
Malnutrition could lead to 'diarrhoea, malaria and pneumonia', expert warns
If someone goes hungry, this can lead to a range of complications, says expert. (Source: Daily Express - Health)
Source: Daily Express - Health - October 23, 2022 Category: Consumer Health News Source Type: news
Toilet problems: The Covid symptom appearing in up to one in five double or triple jabbed
Diarrhoea can strike at the start of a Covid infection and last a week. (Source: Daily Express - Health)
Source: Daily Express - Health - October 22, 2022 Category: Consumer Health News Source Type: news
Positive new data for Roche ’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatalThe JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trialLonger-term safety data consistent with that previously seen in earlier trials and low study drop-out rateEvrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi ® (risdiplam) in...
Source: Roche Media News - October 12, 2022 Category: Pharmaceuticals Source Type: news
Positive new data for Roche ’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatalThe JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trialLonger-term safety data consistent with that previously seen in earlier trials and low study drop-out rateEvrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi ® (risdiplam) in...
Source: Roche Investor Update - October 12, 2022 Category: Pharmaceuticals Source Type: news
Got IBS? It could be down to statins, ibuprofen... or even your acid reflux pills
Caroline, who works in customer services and lives near Penzance, Cornwall, was seven when she started suffering stomach cramps and diarrhoea. (Source: the Mail online | Health)
Source: the Mail online | Health - October 11, 2022 Category: Consumer Health News Source Type: news
Statement by WHO Regional Director on health needs in Syria
21 September 2022 – Over the past 3 days during my visit here in Damascus and to Daraa governorate, I have seen firsthand the devastating impact of war, economic instability and sanctions on innocent Syrians whose health even now continues to deteriorate.
In Daraa, once a hotspot of intense fighting and where parts of the governorate still remain in ruins, I met an elderly lady undergoing dialysis treatment who burst into tears as she spoke to me about her medical condition, and the fate that had befallen her country. Sobbing, she turned to me and asked, “What has happened to us?”
It was a hard question for me to a...
Source: WHO EMRO News - September 21, 2022 Category: Middle East Health Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Uganda: Efforts to Address Vitamin A Deficiency Miss the Mark
[The Conversation Africa] Vitamin A deficiency is the leading cause of preventable childhood blindness. It also increases the risk of death from common childhood illnesses such as diarrhoea. There are several ways to fight this public health threat: giving children vitamin A supplements; promoting more diverse diets; fortifying food; and bio-fortifying crops. Nutrition campaigns can go with these efforts. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 23, 2022 Category: African Health Source Type: news
Nigeria: Federal Govt Introduces Vaccine to Fight 50,000 Diarrhoea Deaths Annually
[Leadership] Federal government has said that about 50,000 deaths occur in children under five years in Nigeria as a result of rotavirus infection, saying vaccination against the virus will avert these deaths. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 23, 2022 Category: African Health Source Type: news
South Africa: Mother Dead, Scores Sick With Diarrhoea As Polluted Tap Water Confirmed
[Daily Maverick] In response to questions from Our Burning Planet after the death of Rashnie Baijnath, the eThekwini Municipality confirmed that tap water in the Birchwood area, west of the city, 'does not meet acceptable standards for human consumption'. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 22, 2022 Category: African Health Source Type: news
Gambia: Mayoress Lowe Extends Magnanimity to Banjul Flood Victims As Cases of Diarrhoea Reported
[The Point] Rohey Malick Lowe, the mayoress of Banjul over the weekend embarked on a series of visits to flood victims in Banjul amid the heavy downpour. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 10, 2022 Category: African Health Source Type: news
European Commission Approves IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep ...
Source: Johnson and Johnson - August 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
